Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GEYMS: Japan's First CAD for Digital Mammography
February 9, 2004
- REGULATORY NEWS IN BRIEF
February 9, 2004
- 1st 3Qtrs Business Results
February 9, 2004
- ON THE MOVE
February 9, 2004
- 1st 3Qtrs Business Results
February 9, 2004
- Mochida's Reorganization Showing Steady Progress: Pres. Mochida
February 9, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 9, 2004
- Overview of US Drug Industry, Healthcare Presented: JPMA Seminar
February 9, 2004
- 1st 3Qtrs Business Results
February 9, 2004
- Antihistamic Drugs Marketing Stiffer Competition (2)
February 9, 2004
- Approval for Levitra, Sandostatin LAR Recommended
February 9, 2004
- BUSINESS NEWS IN BRIEF
February 9, 2004
- Website News
February 9, 2004
- BULLETIN
February 9, 2004
- Gov't-managed Health Insurance Reports 1st Surplus in 10 Yrs
February 9, 2004
- Cultural Sensitivity Is Very Important: Mr Mazzo of AMO
February 9, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 9, 2004
- M-VAC Therapy Approved
February 9, 2004
- Anunal Business Results
February 9, 2004
- Approval of 15 New Drugs Notified
February 9, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…